Digest Network Come funziona
Network
/
Società
Ha
Non verificato

Hansa Biopharma AB

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaImpreseSanità

19 comunicati stampa

Guarda tutti i comunicati
21/03/2025
Farmaceutica
Sanità
Economia
Biologia
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
11/03/2025
Farmaceutica
Sanità
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
06/02/2025
Farmaceutica
Sanità
Imprese
Biologia
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
07/01/2025
Farmaceutica
Sanità
Biologia
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
17/12/2024
Farmaceutica
Sanità
Biologia
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
05/12/2024
Farmaceutica
Sanità
Economia
Start-up
Biologia
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
03/12/2024
Farmaceutica
Sanità
Economia
Start-up
Biologia
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
30/10/2024
Farmaceutica
Sanità
Media
Comunicazione
Multimedialità
Editoria elettronica
Finanza
Biologia
Hansa Biopharma to Attend Truist Securities BioPharma Symposium
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
17/10/2024
Farmaceutica
Sanità
Economia
Imprese
Biologia
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0
07/10/2024
Farmaceutica
Sanità
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
Fonte
Hansa Biopharma AB
Emittente
PR News Wire
1,00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0